Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI

Fan Pu, Mani Salarian, Shenghui Xue, Jingjuan Qiao, Jie Feng, Shanshan Tan, Anvi Patel, Xin Li, Kenza Mamouni, Khan Hekmatyar, Juan Zou, Daqing Wu, Jenny J. Yang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Prostate-specific membrane antigen (PSMA) is one of the most specific cell surface markers for prostate cancer diagnosis and targeted treatment. However, achieving molecular imaging using non-invasive MRI with high resolution has yet to be achieved due to the lack of contrast agents with significantly improved relaxivity for sensitivity, targeting capabilities and metal selectivity. We have previously reported our creation of a novel class of protein Gd3+ contrast agents, ProCA32, which displayed significantly improved relaxivity while exhibiting strong Gd3+ binding selectivity over physiological metal ions. In this study, we report our effort in further developing biomarker-targeted protein MRI contrast agents for molecular imaging of PSMA. Among three PSMA targeted contrast agents engineered with addition of different molecular recognition sequences, ProCA32.PSMA exhibits a binding affinity of 1.1 ± 0.1 μM for PSMA while the metal binding affinity is maintained at 0.9 ± 0.1 × 10-22 M. In addition, ProCA32.PSMA exhibits r1 of 27.6 mM-1 s-1 and r2 of 37.9 mM-1 s-1 per Gd (55.2 and 75.8 mM-1 s-1 per molecule r1 and r2, respectively) at 1.4 T. At 7 T, ProCA32.PSMA also has r2 of 94.0 mM-1 s-1 per Gd (188.0 mM-1 s-1 per molecule) and r1 of 18.6 mM-1 s-1 per Gd (37.2 mM-1 s-1 per molecule). This contrast capability enables the first MRI enhancement dependent on PSMA expression levels in tumor bearing mice using both T1 and T2-weighted MRI at 7 T. Further development of these PSMA-targeted contrast agents are expected to be used for the precision imaging of prostate cancer at an early stage and to monitor disease progression and staging, as well as determine the effect of therapeutic treatment by non-invasive evaluation of the PSMA level using MRI.

Original languageEnglish (US)
Pages (from-to)12668-12682
Number of pages15
JournalNanoscale
Volume8
Issue number25
DOIs
StatePublished - Jul 7 2016

Fingerprint

Molecular imaging
Antigens
Magnetic resonance imaging
Contrast Media
Proteins
Membranes
Molecules
Bearings (structural)
Metals
human glutamate carboxypeptidase II
Molecular recognition
Biomarkers
Metal ions
Tumors

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Pu, F., Salarian, M., Xue, S., Qiao, J., Feng, J., Tan, S., ... Yang, J. J. (2016). Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI. Nanoscale, 8(25), 12668-12682. https://doi.org/10.1039/c5nr09071g

Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI. / Pu, Fan; Salarian, Mani; Xue, Shenghui; Qiao, Jingjuan; Feng, Jie; Tan, Shanshan; Patel, Anvi; Li, Xin; Mamouni, Kenza; Hekmatyar, Khan; Zou, Juan; Wu, Daqing; Yang, Jenny J.

In: Nanoscale, Vol. 8, No. 25, 07.07.2016, p. 12668-12682.

Research output: Contribution to journalArticle

Pu, F, Salarian, M, Xue, S, Qiao, J, Feng, J, Tan, S, Patel, A, Li, X, Mamouni, K, Hekmatyar, K, Zou, J, Wu, D & Yang, JJ 2016, 'Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI', Nanoscale, vol. 8, no. 25, pp. 12668-12682. https://doi.org/10.1039/c5nr09071g
Pu, Fan ; Salarian, Mani ; Xue, Shenghui ; Qiao, Jingjuan ; Feng, Jie ; Tan, Shanshan ; Patel, Anvi ; Li, Xin ; Mamouni, Kenza ; Hekmatyar, Khan ; Zou, Juan ; Wu, Daqing ; Yang, Jenny J. / Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI. In: Nanoscale. 2016 ; Vol. 8, No. 25. pp. 12668-12682.
@article{64dee4ccf22143b69e8293fc874e5fb5,
title = "Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI",
abstract = "Prostate-specific membrane antigen (PSMA) is one of the most specific cell surface markers for prostate cancer diagnosis and targeted treatment. However, achieving molecular imaging using non-invasive MRI with high resolution has yet to be achieved due to the lack of contrast agents with significantly improved relaxivity for sensitivity, targeting capabilities and metal selectivity. We have previously reported our creation of a novel class of protein Gd3+ contrast agents, ProCA32, which displayed significantly improved relaxivity while exhibiting strong Gd3+ binding selectivity over physiological metal ions. In this study, we report our effort in further developing biomarker-targeted protein MRI contrast agents for molecular imaging of PSMA. Among three PSMA targeted contrast agents engineered with addition of different molecular recognition sequences, ProCA32.PSMA exhibits a binding affinity of 1.1 ± 0.1 μM for PSMA while the metal binding affinity is maintained at 0.9 ± 0.1 × 10-22 M. In addition, ProCA32.PSMA exhibits r1 of 27.6 mM-1 s-1 and r2 of 37.9 mM-1 s-1 per Gd (55.2 and 75.8 mM-1 s-1 per molecule r1 and r2, respectively) at 1.4 T. At 7 T, ProCA32.PSMA also has r2 of 94.0 mM-1 s-1 per Gd (188.0 mM-1 s-1 per molecule) and r1 of 18.6 mM-1 s-1 per Gd (37.2 mM-1 s-1 per molecule). This contrast capability enables the first MRI enhancement dependent on PSMA expression levels in tumor bearing mice using both T1 and T2-weighted MRI at 7 T. Further development of these PSMA-targeted contrast agents are expected to be used for the precision imaging of prostate cancer at an early stage and to monitor disease progression and staging, as well as determine the effect of therapeutic treatment by non-invasive evaluation of the PSMA level using MRI.",
author = "Fan Pu and Mani Salarian and Shenghui Xue and Jingjuan Qiao and Jie Feng and Shanshan Tan and Anvi Patel and Xin Li and Kenza Mamouni and Khan Hekmatyar and Juan Zou and Daqing Wu and Yang, {Jenny J.}",
year = "2016",
month = "7",
day = "7",
doi = "10.1039/c5nr09071g",
language = "English (US)",
volume = "8",
pages = "12668--12682",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "25",

}

TY - JOUR

T1 - Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI

AU - Pu, Fan

AU - Salarian, Mani

AU - Xue, Shenghui

AU - Qiao, Jingjuan

AU - Feng, Jie

AU - Tan, Shanshan

AU - Patel, Anvi

AU - Li, Xin

AU - Mamouni, Kenza

AU - Hekmatyar, Khan

AU - Zou, Juan

AU - Wu, Daqing

AU - Yang, Jenny J.

PY - 2016/7/7

Y1 - 2016/7/7

N2 - Prostate-specific membrane antigen (PSMA) is one of the most specific cell surface markers for prostate cancer diagnosis and targeted treatment. However, achieving molecular imaging using non-invasive MRI with high resolution has yet to be achieved due to the lack of contrast agents with significantly improved relaxivity for sensitivity, targeting capabilities and metal selectivity. We have previously reported our creation of a novel class of protein Gd3+ contrast agents, ProCA32, which displayed significantly improved relaxivity while exhibiting strong Gd3+ binding selectivity over physiological metal ions. In this study, we report our effort in further developing biomarker-targeted protein MRI contrast agents for molecular imaging of PSMA. Among three PSMA targeted contrast agents engineered with addition of different molecular recognition sequences, ProCA32.PSMA exhibits a binding affinity of 1.1 ± 0.1 μM for PSMA while the metal binding affinity is maintained at 0.9 ± 0.1 × 10-22 M. In addition, ProCA32.PSMA exhibits r1 of 27.6 mM-1 s-1 and r2 of 37.9 mM-1 s-1 per Gd (55.2 and 75.8 mM-1 s-1 per molecule r1 and r2, respectively) at 1.4 T. At 7 T, ProCA32.PSMA also has r2 of 94.0 mM-1 s-1 per Gd (188.0 mM-1 s-1 per molecule) and r1 of 18.6 mM-1 s-1 per Gd (37.2 mM-1 s-1 per molecule). This contrast capability enables the first MRI enhancement dependent on PSMA expression levels in tumor bearing mice using both T1 and T2-weighted MRI at 7 T. Further development of these PSMA-targeted contrast agents are expected to be used for the precision imaging of prostate cancer at an early stage and to monitor disease progression and staging, as well as determine the effect of therapeutic treatment by non-invasive evaluation of the PSMA level using MRI.

AB - Prostate-specific membrane antigen (PSMA) is one of the most specific cell surface markers for prostate cancer diagnosis and targeted treatment. However, achieving molecular imaging using non-invasive MRI with high resolution has yet to be achieved due to the lack of contrast agents with significantly improved relaxivity for sensitivity, targeting capabilities and metal selectivity. We have previously reported our creation of a novel class of protein Gd3+ contrast agents, ProCA32, which displayed significantly improved relaxivity while exhibiting strong Gd3+ binding selectivity over physiological metal ions. In this study, we report our effort in further developing biomarker-targeted protein MRI contrast agents for molecular imaging of PSMA. Among three PSMA targeted contrast agents engineered with addition of different molecular recognition sequences, ProCA32.PSMA exhibits a binding affinity of 1.1 ± 0.1 μM for PSMA while the metal binding affinity is maintained at 0.9 ± 0.1 × 10-22 M. In addition, ProCA32.PSMA exhibits r1 of 27.6 mM-1 s-1 and r2 of 37.9 mM-1 s-1 per Gd (55.2 and 75.8 mM-1 s-1 per molecule r1 and r2, respectively) at 1.4 T. At 7 T, ProCA32.PSMA also has r2 of 94.0 mM-1 s-1 per Gd (188.0 mM-1 s-1 per molecule) and r1 of 18.6 mM-1 s-1 per Gd (37.2 mM-1 s-1 per molecule). This contrast capability enables the first MRI enhancement dependent on PSMA expression levels in tumor bearing mice using both T1 and T2-weighted MRI at 7 T. Further development of these PSMA-targeted contrast agents are expected to be used for the precision imaging of prostate cancer at an early stage and to monitor disease progression and staging, as well as determine the effect of therapeutic treatment by non-invasive evaluation of the PSMA level using MRI.

UR - http://www.scopus.com/inward/record.url?scp=84976439439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976439439&partnerID=8YFLogxK

U2 - 10.1039/c5nr09071g

DO - 10.1039/c5nr09071g

M3 - Article

C2 - 26961235

AN - SCOPUS:84976439439

VL - 8

SP - 12668

EP - 12682

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 25

ER -